



PRESS RELEASE

Collectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 27, 2023

June 28, 2023 – New York (N.Y.) – Collectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.

The detailed results of the vote and the resolutions are available on the company's website: <https://www.collectis.com/en/investors/general-meetings/>

About Collectis

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Collectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Collectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Collectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit our website www.collectis.com
Follow Collectis on social media: @collectis, LinkedIn and YouTube

For further information on Collectis, please contact:

Media contact:

Pascalyné Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@collectis.com

Investor Relation contact:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@collectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577